**CelLBxHealth plc Appoints New CEO, Strengthens Board Amidst Strategic Realignment**
**GUILDFORD, UK – January 12, 2026** – CelLBxHealth plc (OTC:ANPCF), a company at the forefront of circulating tumor cell (CTC) intelligence, today announced significant changes to its leadership and board of directors, effective immediately. The appointments signal a renewed focus on strategic growth and enhanced governance as the company navigates the evolving landscape of oncology diagnostics and drug development.
Peter Collins has been appointed Chief Executive Officer, a move that brings experienced leadership to the helm. Concurrently, Klaas de Boer, Kim Oreskovic, and Benjamin Hart have joined the board as Non-Executive Directors. These appointments are expected to inject fresh perspectives and deep industry expertise into the company’s strategic decision-making.
The announcement also marks the upcoming departure of Non-Executive Director Joseph Eid, who will step down from the board on January 31, 2026. The company stated that all necessary disclosures under AIM Rule 17 and Schedule 2(g) have been made, and the information contained in the announcement is considered inside information under the EU Market Abuse Regulation.
This strategic board restructuring follows a period of significant operational development for CelLBxHealth. The company, formerly ANGLE plc, has been actively rebranding and consolidating its focus on its Parsortix® platform, a technology designed to harvest CTCs from blood for comprehensive downstream analysis. This includes applications in research, drug development, and clinical oncology.
The addition of new directors with extensive life sciences and operational backgrounds is particularly noteworthy. Klaas de Boer, for instance, brings a wealth of experience in venture capital and scaling technology companies, potentially signaling a drive towards securing further investment and optimizing operational efficiency. Kim Oreskovic’s background in clinical diagnostics and assay development is likely to bolster the company’s efforts in expanding its laboratory services and developing new diagnostic tests. Benjamin Hart’s expertise in technology partnerships and corporate development could be crucial in forging new alliances and exploring strategic acquisitions.
The market has reacted to recent governance shifts with caution, as evidenced by historical stock performance following prior leadership announcements. The current share price, trading near its 52-week low, suggests that investors will be closely scrutinizing the new board’s ability to translate its collective expertise into tangible strategic advancements and commercial success. The elevated trading volume preceding this announcement indicates a heightened level of investor interest in the company’s future direction.
The company’s strategic focus appears to be on three key pillars: accelerating product sales of the Parsortix® platform, enhancing its laboratory services for clinical trial support, and developing proprietary Lab Developed Tests (LDTs). The new board composition is well-suited to support these objectives, providing a blend of operational oversight, scientific acumen, and strategic guidance.
Jan Groen, Executive Chair of CelLBxHealth plc, commented on the appointments: “We welcome Peter and our new non-executive directors to the board. Their extensive expertise, combined with additional life sciences experience, will significantly enhance the board’s capabilities as we focus on strategic opportunities and delivering long-term shareholder value. We would also like to thank Joseph for his assistance over his tenure and wish him all the best for the future.”
The company’s proprietary Parsortix® platform and its GCLP-certified UK laboratory are central to its value proposition. By focusing on CTC intelligence, CelLBxHealth aims to provide critical insights that can guide therapeutic decisions and accelerate the development of novel cancer treatments. The effective implementation of the new leadership’s strategies will be key to unlocking the full potential of these assets.
**About CelLBxHealth plc:**
CelLBxHealth plc is a leading CTC intelligence company specializing in innovative circulating tumor cell (CTC) solutions for use in research, drug development, and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis, including whole-cell imaging, proteomic profiling, and full genomic workflows. The company’s commercial activities focus on product sales, laboratory services, and Lab Developed Tests (LDTs).
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/15614.html
